Laurus Labs Q2 Review: Brokerages Split As Jefferies Raises Target, Two Retain Sell
Jefferies and Goldman Sachs rate stocks including Laurus Labs.
· NDTV Profit
Laurus Labs more than doubled its Q2 net profit as revenue rose 33.5% and EBITDA surged 86.3%. Jefferies raised its target price to Rs 2,100, while Kotak and Goldman Sachs retained Sell ratings, citing valuation concerns despite improving growth prospects.
The analysis
Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- Brokerage calls from Jefferies and Goldman Sachs, with ratings on the stocks named. The stocks: Laurus Labs.
- Over three months: Laurus Labs +26.0% against Pharma & Healthcare -2.1% (28.1 points ahead).
- Trading well above normal today: Laurus Labs at 5.2 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Laurus LabsLAURUSLABS · Pharma & Healthcare | ₹2,405.50 | +7.2% | +13.4% | +26.0% | +7.2% | 5.2× | — |
Pharma & Healthcare
1M -3.2% · 3M -2.1%
Laurus Labs
Prices as of 30 Oct 2026, 15:31 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
India's pharma, healthcare deal volumes rise 23% in Q3 2026: Report
Syngene International shares surge 12%, biggest 1-day gain in 6 years; what drove the rally despite a Q2 profit drop?
Jio Platforms shares to be available under MTF from Day 1. What should investors know?